The decision
Effective 1 July 2023, the Therapeutic Goods Administration (TGA) rescheduled psilocybin and MDMA from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines). This decision allows specifically authorised psychiatrists to prescribe:
Depression (TRD)
Disorder (PTSD)
How we got here
Why it matters
Treatment-resistant depression affects roughly one-third of people diagnosed with major depressive disorder — those for whom standard antidepressants have failed. For this population, options have historically been extremely limited.
Clinical trials suggest that psilocybin-assisted therapy can produce meaningful and lasting remission after just one or two sessions, with a safety profile that compares favourably to existing medications. The mechanism appears to involve a temporary dissolution of rigid patterns of thought — the neural correlates of the "default mode network" are significantly suppressed.
This is a medical and legal development I find worth paying attention to — not as advocacy, but as evidence that our regulatory frameworks can adapt when the science accumulates to a threshold. Psilocybin has been used ceremonially for thousands of years; the clinical formalisation of that use is a recent, careful, and for many people, life-changing development.